(per-am-pa-nel) ,


(trade name)


Therapeutic: anticonvulsants
Pharmacologic: glutamate receptor antagonists
Pregnancy Category: C
Drug schedule to be determined after DEA review.


Adjunctive treatment (with other anti-epileptic drugs [AEDs])of partial-onset seizures with or without secondarily generalized seizures in epileptic patients ≥12 yr.


Acts as a non-competitive α-amino-3–hydroxy-5–methyl-4–isoxazolepropionic acid (AMPA) antagonist on post-synaptic neuronal glutamate (excitatory) receptors.

Therapeutic effects

Decreased incidence and severity of partial-onset seizures.


Absorption: Rapidly and completely absorbed following oral administration.
Distribution: Unknown.
Protein Binding: 95–96%.
Metabolism and Excretion: Extensively metabolized by CYP3A4/5 enzyme systems; excreted in urine and feces primarily as metabolites.
Half-life: 105 hr.

Time/action profile

POunknownunknown2 wk
†Duration of effects following cessation.


Contraindicated in: Strong P450 inducers (other than AEDs); Severe hepatic impairment.
Use Cautiously in: History of homicidal/suicidal ideation or other psychiatric/behavioral issues; Geriatric: Increased risk of adverse reactions, slower titration recommended; Obstetric: Use in pregnancy only when potential benefits outweighs potential fetal risks.; Lactation: Use cautiously; Pediatric: Safe and effective use in children <12 yr has not been established.

Adverse Reactions/Side Effects

Central nervous system

  • dizziness (most frequent)
  • drowsiness (most frequent)
  • headache (most frequent)
  • aggression
  • anger
  • fatigue
  • psychiatric/behavioral problems
  • hostility
  • irritability
  • suicidal ideation
  • vertigo


  • weight gain


  • ataxia
  • balance disorder
  • gait disturbance


  • falls


Drug-Drug interaction

Doses >12 mg/day may ↓ effectiveness of levonorgestrel-containing hormonal contraceptives. CYPP450 inducers including carbamazepine, oxcarbazepine, phenobarbital, phenytoin, primidone, and topiramate can ↓ levels and effectiveness; careful monitoring is required especially during initiation and withdrawal. Dosage adjustments may be required. ↑ risk of CNS depression with other CNS depressants including alcohol, sedating antihistamines, barbiturates, benzodiazepines, opioids and sedative/hypnotics.Levels and effectiveness may be ↓ by St. John's wort; concurrent use should be avoided.


Oral (Adults and Children ≥12 yr) 2 mg once daily at bedtime initially, may be increased by 2 mg weekly up to 4–12 mg daily; Concurrent enzyme-inducers—4 mg once daily at bedtime initially may be increased by 2 mg weekly up to 12 mg daily. Daily dose should not exceed 12 mg.
Oral (Geriatric Patients ) 2 mg once daily at bedtime initially, may be increased by 2 mg every 2 wk up to 4–12 mg daily; Concurrent enzyme-inducers—4 mg once daily at bedtime initially may be increased by 2 mg every 2 wk up to 12 mg daily. Daily dose should not exceed 12 mg.

Hepatic Impairment

Oral (Adults and Children ≥12 yr) Mild hepatic impairment—2 mg once daily at bedtime initially, may be increased by 2 mg every 2 wk up to 6 mg daily; Concurrent enzyme-inducers—4 mg once daily at bedtime initially may be increased by 2 mg every 2 wk up to 6 mg daily. Daily dose should not exceed 6 mg; Moderate hepatic impairment— 2 mg once daily at bedtime initially, may be increased by 2 mg after 2 wk up to 4 mg daily; Concurrent enzyme-inducers—4 mg once daily at bedtime ; daily dose should not exceed 4 mg.


Tablets: 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, 12 mg

Nursing implications

Nursing assessment

  • Assess location, duration, and characteristics of seizure activity. Institute seizure precautions. Assess response to and continued need for perampanel periodically during therapy.
  • Monitor closely for notable changes in behavior that could indicate the emergence or worsening of suicidal thoughts or behavior, new or worse aggressive behavior, or depression.

Potential Nursing Diagnoses

Risk for injury (Indications)


  • Oral: Administer once daily at bedtime.

Patient/Family Teaching

  • Instruct patient to take perampanel as directed. Miss doses should be omitted and dosing resumed the following day. Notify health care professional if more than 1 day of dosing is missed. Medication should be gradually discontinued, do not stop abruptly, to prevent seizures. Advise patient to read the Medication Guide prior to taking ezogabine and with each Rx refill in case of changes.
  • May cause dizziness, sleepiness, fatigue and gait disturbance, increasing risk of falls. Caution patient to avoid driving or other activities requiring alertness until response to medication is known.
  • Inform patients and families of risk of suicidal thoughts and behavior (behavioral changes, emergency or worsening signs and symptoms of depression, unusual changes in mood, or emergence of suicidal thoughts, behavior, or thoughts of self-harm) and aggressive behavior (hostility, anger, anxiety, irritability, being suspicious or distrustful, believing things that are not true). Advise that these should be reported to health care professional immediately.
  • Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and consult health care professional before taking any new medications, especially carbamazepine, phenytoin, oxcarbazepine, rifampin, and St. John's Wort. Advise patient to avoid taking other CNS depressants or alcohol.
  • Perampanel decreases efficacy of levonorgestrel; advise patients to use a non-hormonal form of birth control during therapy. Advise female patients to notify health care professional if pregnancy is planned or suspected or if breast feeding. Encourage pregnant patients to enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry by calling 1-888-233-2334; information is available at

Evaluation/Desired Outcomes

  • Decreased seizure activity.
References in periodicals archive ?
announced today that the latest data on its antiepileptic drugs (AED) perampanel (product name: Fycompa) and rufinamide (product name: Inovelon, U.
Nov 02, 2015: Eisai Presents Results From Phase III Trial of Antiepileptic Drug Perampanel as Adjunctive Therapy for Refractory Partial-Onset Seizures Conducted in Asia Including Japan 84
sup][73],[88] Perampanel, a selective AMPA receptor antagonist, however, failed to effect statistically significant improvement in motor symptoms and motor fluctuations of levodopa-treated patients with moderately advanced PD in clinical trials.
Perampanel is currently licensed in South Africa only for the adjunctive treatment of partial-onset seizures, with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older.
Revised and updated, this edition includes the drugs perampanel and retigabine (ezogabine), updated pharmacokinetic interactions, suggested pediatric dosing schedules for several drugs, discussion of bone health and vitamin D monitoring and supplementation for selected drugs, additional adverse effects and recommended precautions and monitoring, and information on teratogenicity in the sections on pregnancy.
Animal data for the anticonvulsant perampanel (Fycompa) suggest risk, but the absence of human pregnane experience prevents a full assessment of the embryo-fetal risk.
Perampanel has been approved for the treatment of partial onset seizures in epilepsy patients aged 12 years or older.
Perampanel, a selective, noncompetitive alpha-amino-3-hydroxy-5-methyl-4-isoxa-zolepropionic acid (AMPA) receptor antagonist was tested as an add-on therapy for partial-onset seizures in the first of three multinational, placebo-controlled trials.
Perampanel is a drug used for the treatment of seizures associated with epilepsy.
This edition has new drugs, including aclidinium bromide, felbamate, icosapent ethyl, linaclotide, peginesatide acetate, perampanel, rotigotine, and teriflunomide, and updated group monographs for antipsychotic agents, benzodiazepenes, calcium channel blocking agents, estrogens, macrolides, opioid analgesics, proton pump inhibitors, selective serotonin reuptake inhibitors, and serotonin 5-HT1 receptor agonists.
The G-BA concluded in March 2013 that the submitted assessment data comparing perampanel to lamotrigine or topiramate was insufficient and that the additional benefit of perampanel was thus unproven.